Abstract
Achalasia is a primary esophageal motility disorder characterized by aperistalsis and incomplete or absent relaxation of the lower esophageal sphincter (LES). The cause of the disease remains elusive and there is no intervention that improves the esophageal body function. Currently, treatment options focus on palliation of symptoms by reducing the LES pressure. The most effective and well-tolerated treatments continue to be the laparoscopic Heller myotomy and endoscopic pneumatic dilation; however, newer techniques (eg, peroral endoscopic myotomy and self-expanding metal stents) show promise. Botulinum toxin and pharmacologic therapy are reserved for those who are unable to undergo more effective therapies. Treatment options should be tailored to the patient, using current predictors of outcome such as the patient’s age and post-treatment LES pressures. The aim of this article is to highlight current literature and provide an up-to-date approach to the treatment of achalasia.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance
Mayberry JF. Epidemiology and demographics of achalasia. Gastrointest Endosc Clin N Am. 2001;11(2):235–48. v.
Leeuwenburgh I, Scholten P, Alderliesten J, et al. Long-term esophageal cancer risk in patients with primary achalasia: a prospective study. Am J Gastroenterol. 2010;105(10):2144–9.
Bortolotti M. Medical therapy of achalasia: a benefit reserved for few. Digestion. 1999;60(1):11–6.
Gelfond M, Rozen P, Gilat T. Isosorbide dinitrate and nifedipine treatment of achalasia: a clinical, manometric and radionuclide evaluation. Gastroenterology. 1982;83(5):963–9.
Bortolotti M, Mari C, Lopilato C, et al. Effects of sildenafil on esophageal motility of patients with idiopathic achalasia. Gastroenterology. 2000;118(2):253–7.
Eherer AJ, Schwetz I, Hammer HF, et al. Effect of sildenafil on oesophageal motor function in healthy subjects and patients with oesophageal motor disorders. Gut. 2002;50(6):758–64.
Pasricha PJ, Ravich WJ, Hendrix TR, et al. Intrasphincteric botulinum toxin for the treatment of achalasia. N Engl J Med. 1995;332(12):774–8.
Pasricha PJ, Rai R, Ravich WJ, et al. Botulinum toxin for achalasia: long-term outcome and predictors of response. Gastroenterology. 1996;110(5):1410–5.
Annese V, Bassotti G, Coccia G, et al. A multicentre randomised study of intrasphincteric botulinum toxin in patients with oesophageal achalasia. GISMAD Achalasia Study Group Gut. 2000;46(5):597–600.
Kolbasnik J, Waterfall WE, Fachnie B, et al. Long-term efficacy of Botulinum toxin in classical achalasia: a prospective study. Am J Gastroenterol. 1999;94(12):3434–9.
D’Onofrio V, Miletto P, Leandro G, Iaquinto G. Long-term follow-up of achalasia patients treated with botulinum toxin. Dig Liver Dis. 2002;34(2):105–10.
Tuset JA, Lujan M, Huguet JM, et al. Endoscopic pneumatic balloon dilation in primary achalasia: predictive factors, complications, and long-term follow-up. Dis Esophagus. 2009;22(1):74–9.
Kroupa R, Hep A, Dolina J, et al. Combined treatment of achalasia—botulinum toxin injection followed by pneumatic dilatation: long-term results. Dis Esophagus. 2010;23(2):100–5.
Vela MF, Richter JE, Khandwala F, et al. The long-term efficacy of pneumatic dilatation and Heller myotomy for the treatment of achalasia. Clin Gastroenterol Hepatol. 2006;4(5):580–7.
Radaelli F, Paggi S, Terreni N, et al. Acute reversible gastroparesis and megaduodenum after botulinum toxin injection for achalasia. Gastrointest Endosc. 2010;71(7):1326–7.
O’Connor JB, Singer ME, Imperiale TF, et al. The cost-effectiveness of treatment strategies for achalasia. Dig Dis Sci. 2002;47(7):1516–25.
Vaezi MF, Richter JE. Current therapies for achalasia: comparison and efficacy. J Clin Gastroenterol. 1998;27(1):21–35.
Kadakia SC, Wong RK. Graded pneumatic dilation using Rigiflex achalasia dilators in patients with primary esophageal achalasia. Am J Gastroenterol. 1993;88(1):34–8.
• Hulselmans M, Vanuytsel T, Degreef T, et al.: Long-term outcome of pneumatic dilation in the treatment of achalasia. Clin Gastroenterol Hepatol. 2010;8(1):30–5. This study by Hulselmans et al. clearly outlines a successful pneumatic dilation technique based on a measured LES pressure endpoint that leads to long-term success rates. It also strongly substantiates prior findings that older populations are more likely to respond to pneumatic dilation and younger populations are likely to fail this therapeutic intervention.
Campos GM, Vittinghoff E, Rabl C, et al. Endoscopic and surgical treatments for achalasia: a systematic review and meta-analysis. Ann Surg. 2009;249(1):45–57.
Zerbib F, Thetiot V, Richy F, et al. Repeated pneumatic dilations as long-term maintenance therapy for esophageal achalasia. Am J Gastroenterol. 2006;101(4):692–7.
Eckardt VF, Aignherr C, Bernhard G. Predictors of outcome in patients with achalasia treated by pneumatic dilation. Gastroenterology. 1992;103(6):1732–8.
Ponce J, Garrigues V, Pertejo V, et al. Individual prediction of response to pneumatic dilation in patients with achalasia. Dig Dis Sci. 1996;41(11):2135–41.
Vela MF, Richter JE, Wachsberger D, et al. Complexities of managing achalasia at a tertiary referral center: use of pneumatic dilatation, Heller myotomy, and botulinum toxin injection. Am J Gastroenterol. 2004;99(6):1029–36.
Sharma P, Kozarek R. Role of esophageal stents in benign and malignant diseases. Am J Gastroenterol. 2010;105(2):258–73. quiz 74.
Howard JM, Mongan AM, Manning BJ, et al. Outcomes in achalasia from a surgical unit where pneumatic dilatation is first-line therapy. Dis Esophagus. 2010;23(6):465–72.
Moawad FJ, Maydonovitch CL, Horwhat JD, Wong RK. Complications with pneumatic dilation. Clin Gastroenterol Hepatol. 2010;8(8):734–5. author reply 5.
Zhu YQ, Cheng YS, Tang GY, et al. Comparison of temporary stent insertion with pneumatic dilation of the same diameter in the treatment of achalasia patients: a retrospective study. J Gastroenterol Hepatol. 2010;25(3):499–505.
Zhao JG, Li YD, Cheng YS, et al. Long-term safety and outcome of a temporary self-expanding metallic stent for achalasia: a prospective study with a 13-year single-center experience. Eur Radiol. 2009;19(8):1973–80.
Li YD, Cheng YS, Li MH, et al. Temporary self-expanding metallic stents and pneumatic dilation for the treatment of achalasia: a prospective study with a long-term follow-up. Dis Esophagus. 2010;23(5):361–7.
De Palma GD, Lovino P, Masone S, et al. Self-expanding metal stents for endoscopic treatment of esophageal achalasia unresponsive to conventional treatments. Long-term results in eight patients. Endoscopy. 2001;33(12):1027–30.
Tsiaoussis J, Pechlivanides G, Gouvas N, et al. Patterns of esophageal acid exposure after laparoscopic Heller’s myotomy and Dor’s fundoplication for esophageal achalasia. Surg Endosc. 2008;22(6):1493–9.
Rebecchi F, Giaccone C, Farinella E, et al. Randomized controlled trial of laparoscopic Heller myotomy plus Dor fundoplication versus Nissen fundoplication for achalasia: long-term results. Ann Surg. 2008;248(6):1023–30.
Boeckxstaens GE, Annese V, Bruley des Varannes S, et al. The European achalasia trial: a randomized multi-centre trial comparing endoscopic pneumodilation and laparoscopic myotomy as primary treatment of idiopathic achalasia. Gastroenterology. 2010;138(Supplemental 1):s53.
Zaninotto G, Costantini M, Rizzetto C, et al. Four hundred laparoscopic myotomies for esophageal achalasia: a single centre experience. Ann Surg. 2008;248(6):986–93.
Eldaif SM, Mutrie CJ, Rutledge WC, et al. The risk of esophageal resection after esophagomyotomy for achalasia. Ann Thorac Surg. 2009;87(5):1558–62. discussion 62–3.
• Inoue H, Minami H, Kobayashi Y, et al.: Peroral endoscopic myotomy (POEM) for esophageal achalasia. Endoscopy 2010;42(4):265–71. This study of a novel treatment for achalasia is the largest to date demonstrating excellent short-term outcomes from POEM and raising the expectations of positive results from larger studies with long-term outcomes.
Perretta S, Dallemagne B, Allemann P, Marescaux J. Multimedia manuscript. Heller myotomy and intraluminal fundoplication: a NOTES technique. Surg Endosc. 2010;24(11):2903.
Acknowledgments
The opinions are solely those of the authors and do not represent an endorsement by the Department of the Defense. There are no restrictions on its use. The authors do not have any commercial or proprietary interest in any drug, device, or equipment mentioned in the manuscript. There are no conflicts of interest, financial disclosures, grant support, or writing assistance.
Conflicts of interest
J.G. Cheatham–none; R.K.H. Wong—none.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cheatham, J.G., Wong, R.K.H. Current Approach to the Treatment of Achalasia. Curr Gastroenterol Rep 13, 219–225 (2011). https://doi.org/10.1007/s11894-011-0190-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11894-011-0190-z